Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept cookies
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Volodymyr Zelenskyy hails soldiers as Ukraine steps up attacks in new offensive phase
    • Spain frets over German threat to boycott ‘drought strawberries’
    • Saudi Arabia seeks to boost oil price with output cut of 1mn barrels a day
    • Arctic chill: western nations fear China and Russia will exploit regional tensions
    • India blames train crash on signal failure as death toll nears 300
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Companies
      Sections
      • Companies Home
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
      Most Read
      • US banks prepare for losses in rush for commercial property exit
      • Axa to buy French film studio in €150mn deal
      • Apple unveils Vision Pro ‘mixed reality’ headset
      • Boiler makers up in arms over UK heat pump targets
      • Hollywood actors seek new deal over use of AI ‘digital doubles’
    • Tech
    • Markets
      Sections
      • Markets Home
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      Most Read
      • Live news: Bearish Morgan Stanley tips 16% drop in S&P 500 earnings in 2023
      • Saudi Arabia seeks to boost oil price with output cut of 1mn barrels a day
      • Pension funds recoiling from China, says Dutch asset manager
      • Why the AI boom is not a dotcom redux
      • Investors brace for new law on sovereign debt workouts
    • Climate
    • Opinion
      Sections
      • Opinion Home
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
      Most Read
      • How America is reshaping the global economy
      • Europe’s new success stories are built on high luxury, not high tech
      • The dismal truth about email
      • What the debt ceiling debate missed
      • Why the AI boom is not a dotcom redux
    • Work & Careers
      Sections
      • Work & Careers Home
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
      Most Read
      • Anti-monarchist Graham Smith: The British royals are ‘tax-funded Kardashians’
      • Can a virtual PA turbocharge your career?
      • FT business books: what to read this month
    • Life & Arts
      Sections
      • Life & Arts Home
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
      Most Read
      • My search for the ‘perfect’ all-round swimsuit
      • Sci-fi writer Ted Chiang: ‘The machines we have now are not conscious’
      • The American luxury lifestyle brand storming the Cotswolds
      • A wild ride to South America’s northern tip
      • Why motorcycle gangs will end with a whimper, not a rev
    • HTSI
    MenuSearch
    • Home
    • World
    • US
    • Companies
    • Tech
    • Markets
    • Climate
    • Opinion
    • Work & Careers
    • Life & Arts
    • HTSI
    Financial Times
    SubscribeSign In

    Gonzalo Viña

    Add to myFT Digest

    Add this topic to your myFT Digest for news straight to your inbox

    • Monday, 24 April, 2017
      Pharmaceuticals sector
      Malaria experts set sights on single-shot cure by 2030s

      Scientists seek miracle drug to break parasites’ life cycle

    • Monday, 24 April, 2017
      Life & Arts
      Vital to catch malaria early as drugs lose effectiveness

      Prospect feared of resistance spreading to India and Africa

    • Tuesday, 18 April, 2017
      Special ReportNeglected Tropical Diseases
      More engagement on neglected tropical diseases needed from drugmakers

      Pharma companies must share intellectual property to spur the development of new treatments

    • Wednesday, 5 April, 2017
      Special ReportTomorrow’s Global Business: Raising Capital
      Testing times for the UK’s university spin-off funds

      Investing in intellectual property commercialisation is not without risks

    • Tuesday, 28 February, 2017
      US & Canadian companies
      Valeant shares drop 14% as drugmaker cuts guidance

      Canadian drugmaker has been selling assets but retains net debt of more than $30bn

    • Tuesday, 28 February, 2017
      Pharmaceuticals sector
      Small patient groups hinder progress of clinical trials

      Drugmakers spot rewards despite the organisational difficulties

    • Monday, 27 February, 2017
      Pharmaceuticals sector
      WHO raises alarm over drug-resistant superbugs

      With millions of lives potentially at stake, UN agency issues call for new antibiotics

    • Friday, 17 February, 2017
      UK companies
      AstraZeneca boosted by positive breast cancer trial

      Shares rise on successful outcome for Lynparza, a drug tipped for blockbuster status

    • Thursday, 16 February, 2017
      UK companies
      Shire beats expectations on back of strong sales

      Drugmaker to focus on cutting $22bn debt pile as it targets double-digit growth

    • Thursday, 16 February, 2017
      Pharmaceuticals sector
      Shire clocks up rising sales and profits rise in 2016
    • Thursday, 16 February, 2017
      UK industrial strategy
      UK steps in to plug science funding gap

      Spending on R&D has lagged behind the rest of the OECD countries

    • Thursday, 2 February, 2017
      UK companies
      AstraZeneca hit by falling sales of its bestselling drugs

      Declines in Crestor and Nexium offset emerging markets growth 

    • Thursday, 2 February, 2017
      European companies
      Novo Nordisk cuts profit outlook on higher US political risks

      Danish group is exposed to potential drug price curbs from Trump administration

    • Thursday, 2 February, 2017
      IPOs
      Arix Bioscience targets £100m fundraising with London IPO

      Investor in early-stage drugmakers sets offer price of 207p a share

    • Wednesday, 1 February, 2017
      European companies
      Roche underlines ‘value’ of drugmakers to the US

      Comments come as Swiss drugmaker reports 4% increase in group sales

    • Wednesday, 1 February, 2017
      Pharmaceuticals sector
      Roche 2016 sales come in below forecasts
    • Thursday, 19 January, 2017
      Pharmaceuticals sector
      AstraZeneca exec appointed as GlaxoSmithKline global pharma president
    • Tuesday, 17 January, 2017
      European companies
      AstraZeneca expands trials for key cancer drug

      Move gives company more options but could signal less confidence in initial approach

    • Thursday, 12 January, 2017
      News in-depthEuropean companies
      Sanofi confident it can overturn Praluent patent ruling

      French drugmaker faces questions over how to offset declining Lantus revenues

    • Wednesday, 11 January, 2017
      Pharmaceuticals sector
      Shire to pay $350m to settle kickback allegations over skin product
    • Friday, 6 January, 2017
      UK small companies
      Biotech and pharma companies hope for better in 2017

      Several UK small-cap stocks stand out among their peers as ones to watch

    • Wednesday, 4 January, 2017
      Pharmaceuticals sector
      Cost of pharma M&A deals doubles since 2015

      Cheap credit and need for new drugs create overheated market, analysts warn

    • Thursday, 22 December, 2016
      European companies
      Roche boosted by haemophilia drug test

      Swiss pharma group says treatment showed signs of outperforming others

    • Wednesday, 21 December, 2016
      US & Canadian companies
      Johnson & Johnson and Actelion disclose ‘exclusive’ deal talks

      Drug groups renew negotiations one week after discussions broke down

    • Friday, 16 December, 2016
      Pharmaceuticals sector
      Actavis targeted by UK competition watchdog for 12,000% price rise

      CMA alleges generic drugmaker overcharged NHS for hydrocortisone tablets

    Previous page You are on page 1 Next page

    Useful links

    Support

    View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

    Legal & Privacy

    Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

    Services

    Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT ChannelsFT Schools

    Tools

    PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

    Community & Events

    FT CommunityFT Live EventsFT ForumsFT Board DirectorBoard Director Programme

    More from the FT Group

    Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2023. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
    The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
    Financial Times

    International Edition

    Subscribe for full access
    • Switch to UK Edition

    Top sections

    • Home
    • World
      • Global Economy
      • UK
      • US
      • China
      • Africa
      • Asia Pacific
      • Emerging Markets
      • Europe
      • War in Ukraine
      • Americas
      • Middle East & North Africa
      • Australia & NZ
    • US
      • US Economy
      • US Companies
      • US Politics & Policy
    • Companies
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
    • Tech
    • Markets
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
    • Climate
    • Opinion
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
    • Work & Careers
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
    • Life & Arts
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
    • Personal Finance
      • Property & Mortgages
      • Investments
      • Pensions
      • Tax
      • Banking & Savings
      • Advice & Comment
      • Next Act
    • HTSI
    • Special Reports

    FT recommends

    • Lex
    • Alphaville
    • Lunch with the FT
    • FT Globetrotter
    • #techAsia
    • Moral Money
    • Newsletters
    • Video
    • Podcasts
    • News feed
    • FT Live Events
    • FT Forums
    • Board Director Programme
    • myFT
    • Portfolio
    • Today's Newspaper (ePaper)
    • Crossword
    • Our Apps
    • Help Centre
    • Subscribe
    • Sign In